| Assessment Status | Rapid review complete |
| HTA ID | 21035 |
| Drug | Dupilumab |
| Brand | Dupixent® |
| Indication | For severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 30/08/2021 |
| Rapid review completed | 23/09/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations May 2022.